Claims for Patent: 7,396,530

Summary for Patent: 7,396,530

Title:	Method of treating granuloma annulare or sarcoid
Abstract:	The invention provides a method of alleviating a granuloma annulare or a sarcoid disease by administering to a patient having the disease, a therapeutically effective amount of an LFA-1 antagonist.
Inventor(s):	Goffe; Bernard S. (Seattle, WA)
Assignee:	Genentech, Inc. (South San Francisco, CA)
Application Number:	11/149,031
Patent Claims:	1. A method of alleviating a disseminated granuloma annulare comprising administering to a patient having the disease, a therapeutically effective amount of an LFA-1 antagonist wherein the LFA-1 antagonists is an anti-CD11a antibody. 2. The method of claim 1, wherein the anti-CD11a antibody is efalizumab. 3. The method of claim 2, wherein the antibody is administered at between 0.3 mg/kg to 4 mg/kg. 4. The method of claim 3, wherein the antibody is administered at 1 mg/kg weekly. 5. The method of claim 3, wherein the antibody is administered at 2 mg/kg weekly. 6. The method of claim 3 or claim 4, wherein the patient is administered the antibody at an initial conditioning dose before the therapeutic dose. 7. The method of claim 6, wherein the conditioning dose is 0.7 mg/kg. 8. The method of claim 2, wherein the antibody is administered at an initial conditioning dose of 0.7 mg/kg during the first week followed by a dose of 1 mg/kg weekly for at least 4 weeks. 9. The method of claim 8, wherein the dose of 1 mg/kg is administered for at least 11 weeks. 10. The method of claim 1, wherein the LFA-1 antagonist is administered subcutaneously. 11. The method of any one of claims 4, 5, and 9, wherein the LFA-1 antagonist is administered subcutaneously. 12. The method of claim 1 wherein the LFA-1 antagonist is administered intravenously. 13. The method of claim 1 or 2 wherein the LFA-1 antagonist is administered in conjunction with a second therapeutic agent or an immunosuppressive agent. 14. The method of claim 13, wherein the second therapeutic agent is selected from the group consisting of cyclosporine, isotretinoin, etretinate, topical and systemic corticosteroids, fumaric acid esters, psoralens plus ultraviolet A (PUVA), potassium iodide, pentoxifylline, topical vitamin E, hydroxychloroquine, dapsone, niacinamide, low-dose chlorambucil, clofazimine, and a 5-lipoxygenase inhibitor plus vitamin E. 15. The method of 14, wherein the second therapeutic agent is clofazimine or cyclosporine. 16. The method of claim 14, wherein the second therapeutic agent and the LFA-1 antagonist are administered concurrently. 17. The method of claim 14, wherein the second therapeutic agent and the LFA-1 antagonist are administered sequentially in either order. 18. The method of claim 14, wherein the second therapeutic agent and the LFA-1 antagonist are administered in a combination of concurrently and sequentially in either order. 19. The method of claim 1 wherein the patient is non-responsive to other therapy. 20. The method of claim 1 wherein the granuloma annulare is resolved within 2 months of initiation of therapy with the LFA-1 antagonist.

Details for Patent 7,396,530

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RAPTIVA	efalizumab	Injection	125075	October 27, 2003	7,396,530	2025-06-08